SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Wal-Mart Price Pressure Hurts China Workers: Report
- Fannie Mae to Tighten Lending Standards: Report
- Great Britain, No Longer That Great: Investor
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Euro Shares Record Biggest Drop in 7 Months
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
![]() |
AP Jamie Dimon |
A common refrain in investment circles is that healthcare is recession-proof.
It's less economy-related than it is fundamentals-related, but today comes word out of our partners at "The Wall Street Journal" that Pfizer [PFE
Loading...
()
] is planning to lay off 800 researchers.
But the contrast between the downsizing in big pharma and the picture in the upstart biotech sector can be striking.
This morning while killing time before my live interview with Vertex Pharmaceuticals [VRTX
Loading...
()
] CEO Joshua Boger, he told me that his company took in 11,000 applications last year for 300 positions. "It's tougher than getting into Harvard," said Boger whose company is headquartered in Harvard's home town of Cambridge, MA. And VRTX, which is ramping up for its hepatitis C drug, is still hiring a few people a week.
It's an anecdote. It doesn't mean that biotech is immune from the troubles plaguing the economy, the drug sector and the markets. A lot of money-losing biotechs with no products on the market can't access the capital markets right now. And that's forcing many of them to better conserve what little cash they have on hand. That can mean layoffs and scuttling of earlier stage research and development projects.
The Biotechnology Industry Organization says that's putting innovation at risk and is calling for a federal tax break for baby biotechs that aren't making money. Jamie Dimon doesn't like that idea. In response to a question about it yesterday he said gesturing with one arm and then the other—and I'm paraphrasing a wee bit—"If something stupid happens over here, why would you do something stupid over there?" The audience laughed.
Questions? Comments?









